Fig. 1: PROTAC molecules potently degrade RIPK2 in THP-1 cells.
From: Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
We observed the degradation of RIPK2 in THP-1 cells relative to DMSO control upon treatment with analogous RIPK2 PROTACs employing VHL (1), IAP (2), and cereblon (3) E3 ligase recruiting moieties measured via a capillary-based immunoassay after 18 h treatment (n = 3).
